Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 18 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Pharvaris N.V. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 21 | 21 | 0 |
| Shares | 28.9M | 29.1M | +153.3K (+0.5%) |
| Value | $441.6M | $606.6M | +$165.1M (+37.4%) |
New holders (3)
Institutions that held Pharvaris N.V. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Hudson Bay Capital Management LP | 38,893 | $811.7K | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 17,553 | $366.3K | 0.04% |
| Qube Research & Technologies Ltd | 2,579 | $53.8K | 0.00% |
Sold out (3)
Institutions that held Pharvaris N.V. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Silverarc Capital Management, LLC | 200,000 | $3.03M |
| Lynx1 Capital Management LP | 21,225 | $321.3K |
| JPMorgan Chase & Co | 151 | $2.37K |